PHATHOM PHARMACEUTICALS, INC. (PHAT): Price and Financial Metrics

PHATHOM PHARMACEUTICALS, INC. (PHAT): $11.66

0.03 (+0.26%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

C

Add PHAT to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#205 of 380

in industry

PHAT Price/Volume Stats

Current price $11.66 52-week high $14.45
Prev. close $11.63 52-week low $5.84
Day low $11.41 Volume 193,100
Day high $11.83 Avg. volume 435,230
50-day MA $10.42 Dividend yield N/A
200-day MA $9.89 Market Cap 508.54M

PHAT Stock Price Chart Interactive Chart >


PHATHOM PHARMACEUTICALS, INC. (PHAT) Company Bio


Phathom Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. It develops Vonoprazan, a potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Buffalo Grove, IL.


PHAT Latest News Stream


Event/Time News Detail
Loading, please wait...

PHAT Latest Social Stream


Loading social stream, please wait...

View Full PHAT Social Stream

Latest PHAT News From Around the Web

Below are the latest news stories about PHATHOM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate PHAT as an investment opportunity.

Phathom Pharmaceuticals Reports First Quarter 2023 Results

FLORHAM PARK, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the first quarter of 2023 and provided updates on recent regulatory progress. “This quarter, we made remarkable progress advancing mission-critical priorities that position Phathom to potentially deliver vonoprazan to patients suffering from Eros

Yahoo | May 10, 2023

Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023

Higher H. pylori eradication rates demonstrated with vonoprazan-based regimens vs. lansoprazole triple therapy, regardless of different baseline demographics and clinical characteristicsMeta-analysis shows potassium-competitor acid blockers (PCABs), including vonoprazan, provide a longer duration of pH >4, higher predicted Erosive GERD healing rates, and lower probabilities of failure to achieve healing FLORHAM PARK, N.J., May 09, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: P

Yahoo | May 9, 2023

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team will participate in the following upcoming investor conferences: 22nd Annual Needham Virtual Healthcare Conference, including a scheduled fireside chat on Tuesday, April 18, 2023 at 8:45 a.m. EDT. Management will also participate

Yahoo | April 12, 2023

Phathom (PHAT) Up 8% on Erosive Esophagitis Drug's CRL Update

Phathom Pharmaceuticals (PHAT) announces a regulatory update regarding vonoprazan for the treatment of erosive esophagitis and H. pylori infection. Stock surges 8% following the news.

Yahoo | April 5, 2023

Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch

Favorable feedback following meeting with the U.S. Food and Drug Administration (FDA) allows for planned resubmission of erosive esophagitis new drug application (NDA) this quarterCombined commercial launch of vonoprazan for erosive esophagitis and H. pylori indications expected Q4 2023, if approved FLORHAM PARK, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroi

Yahoo | April 4, 2023

Read More 'PHAT' Stories Here

PHAT Price Returns

1-mo -0.34%
3-mo 33.56%
6-mo 5.33%
1-year 62.85%
3-year -73.50%
5-year N/A
YTD 3.92%
2022 -42.96%
2021 -40.79%
2020 6.68%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!